UGGT2

Across TCGA pan-cancer cohorts, UGGT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UGGT2 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher UGGT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UGGT2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where UGGT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.484	0.775	.013	19	view →
PDAC	DFS	Tertile	All	0.328	0.569	.011	13	view →
LSCC	OS	Median	II,III,IV	0.678	0.886	.014	11	view →
HNSC	DFS	Median	III,IV	0.992	0.913	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UGGT2–LUAD (DFS)

Open the LUAD breakdown →